Nintedanib - CAS 656247-17-5
Catalog number: B0084-262244
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C31H33N5O4
Molecular Weight:
539.62
COA:
Inquire
Targets:
FGFR | VEGFR
Description:
Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM. It exhibits potential antiangiogenic and antineoplastic activities.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-262244 500 mg $279 In stock
Bulk Inquiry
Brife Description:
inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β
Purity:
>98%
Synonyms:
Vargatef; BIBF-1120; BIBF 1120; Intedanib
Solubility:
Water: 9.66 mg/L
MSDS:
Inquire
Application:
the treatment of idiopathic pulmonary fibrosis
InChIKey:
XZXHXSATPCNXJR-ZIADKAODSA-N
InChI:
InChI=1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,32H,15-18,20H2,1-3H3,(H,33,38)/b29-28-
Canonical SMILES:
CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)NC(=C3C4=C(C=C(C=C4)C(=O)OC)NC3=O)C5=CC=CC=C5
1.A fully automated image analysis method to quantify lung fibrosis in the bleomycin-induced rat model.
Seger S;Stritt M;Vezzali E;Nayler O;Hess P;Groenen PMA;Stalder AK PLoS One. 2018 Mar 16;13(3):e0193057. doi: 10.1371/journal.pone.0193057. eCollection 2018.
Intratracheal administration of bleomycin induces fibrosis in the lung, which is mainly assessed by histopathological grading that is subjective. Current literature highlights the need of reproducible and quantitative pulmonary fibrosis analysis. If some quantitative studies looked at fibrosis parameters separately, none of them quantitatively assessed both aspects: lung tissue remodeling and collagenization. To ensure reliable quantification, support vector machine learning was used on digitalized images to design a fully automated method that analyzes two important aspects of lung fibrosis: (i) areas having substantial tissue remodeling with appearance of dense fibrotic masses and (ii) collagen deposition. Fibrotic masses were identified on low magnification images and collagen detection was performed at high magnification. To insure a fully automated application the tissue classifier was trained on several independent studies that were performed over a period of four years. The detection method generates two different values that can be used to quantify lung fibrosis development: (i) percent area of fibrotic masses and (ii) percent of alveolar collagen. These two parameters were validated using independent studies from bleomycin- and saline-treated animals.
2.F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial.
Quintela-Fandino M;Lluch A;Manso L;Calvo I;Cortes J;García-Saenz JA;Gil-Gil M;Martinez-Jánez N;Gonzalez-Martin A;Adrover E;de Andres R;Viñas G;Llombart-Cussac A;Alba E;Guerra J;Bermejo B;Zamora E;Moreno-Anton F;Pernas Simon S;Carrato A;Lopez-Alonso A;Escudero MJ;Campo R;Carrasco E;Palacios J;Mulero F;Colomer R Clin Cancer Res. 2017 Mar 15;23(6):1432-1441. doi: 10.1158/1078-0432.CCR-16-0738. Epub 2016 Sep 1.
Purpose:; We previously detected promising efficacy of neoadjuvant nintedanib (a multityrosine kinase inhibitor, TKI) in early HER2-negative breast cancer. In a preclinical study, we monitored stromal hypoxia with ;18;F-fluoromisonidazole-positron emission tomography (18F-FMISO-PET); we found that reoxygenation of tumors (or lack of it) during a window-of-opportunity (WoO) treatment with TKIs correlated with the benefit (or lack of it) from TKI-plus-chemotherapy combinations. We studied the predictive role of 18F-FMISO-PET for the TKI nintedanib in the neoadjuvant setting in a phase II WoO randomized trial.;Experimental Design:; Patients were randomized to a 14-day WoO of nintedanib preceded and followed by an 18F-FMISO-PET, followed by nintedanib plus weekly paclitaxel (Arm A) or an 18F-FMISO-PET followed by weekly paclitaxel (Arm B) before surgery. The endpoint was residual cancer burden (RCB). The objective was to detect the patients with no response (RCB-III) on the basis of the baseline or evolutive 18F-FMISO-PET values/changes.;Results:; One-hundred and thirty HER2-negative patients were randomized. Seventeen (27.9%), 34 (55.7%), and 8 (13.1%) patients had an RCB of III, II, and I/0, respectively, in Arm A.
3.Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms.
Grillo F;Florio T;Ferraù F;Kara E;Fanciulli G;Faggiano A;Colao A;NIKE Group Endocr Relat Cancer. 2018 Sep;25(9):R453-R466. doi: 10.1530/ERC-17-0531. Epub 2018 May 16.
In the last few years, the therapeutic approach for neuroendocrine neoplasms (NENs) has changed dramatically following the approval of several novel targeted treatments. The multitarget tyrosine kinase inhibitor (MTKI), sunitinib malate, has been approved by Regulatory Agencies in pancreatic NENs. The MTKI class, however, includes several other molecules (approved for other conditions), which are currently being studied in NENs. An in-depth review on the studies published on the MTKIs in neuroendocrine tumors such as axitinib, cabozantinib, famitinib, lenvatinib, nintedanib, pazopanib, sorafenib and sulfatinib was performed. Furthermore, we extensively searched on the Clinical Trial Registries databases worldwide, in order to collect information on the ongoing clinical trials related to this topic. Our systematic analysis on emerging MTKIs in the treatment of gastroenteropancreatic and lung NENs identifies ;in vitro; and ;in vivo; studies, which demonstrate anti-tumor activity of diverse MTKIs on neuroendocrine cells and tumors. Moreover, for the first time in the literature, we report an updated view concerning the upcoming clinical trials in this field: presently, phase I, II and III clinical trials are ongoing and will include, overall, a staggering 1667 patients.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related FGFR Products


CAS 568-72-9 Tanshinone IIA

Tanshinone IIA
(CAS: 568-72-9)

Tanshinone IIA, under the IUPAC name 1,6,6-trimethyl-8,9-dihydro-7H-naphtho[1,2-g][1]benzofuran-10,11-dione, one of the original anthracyclines isolated from Sa...

CAS 928037-13-2 Golvatinib

Golvatinib
(CAS: 928037-13-2)

golvatinib (also known as E7050) is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial ...

CAS 38101-59-6 H-Glu-Trp-OH

H-Glu-Trp-OH
(CAS: 38101-59-6)

H-Glu-Trp-OH inhibits VEGF, which may inhibit angiogenesis.

CAS 728033-96-3 OSI-930

OSI-930
(CAS: 728033-96-3)

OSI-930 is a selective thiophene-derived tyrosine kinase inhibitor with potential antineoplastic activity. Tyrosine kinase inhibitor OSI-930 inhibits stem cell ...

CAS 1708971-72-5 FGFR4-IN-1

FGFR4-IN-1
(CAS: 1708971-72-5)

FGFR4-IN-1 is a potent and selective FGFR4 inhibitor with potential for the treatment of gastric cancer.

CAS 872511-34-7 BGJ-398

BGJ-398
(CAS: 872511-34-7)

BGJ398, also known as NVP-BGJ398, is a pan FGFR kinase inhibitor, and is an orally bioavailable pan inhibitor of human fibroblast growth factor receptors (FGFRs...

CAS 1125780-41-7 SKLB610

SKLB610
(CAS: 1125780-41-7)

SKLB610 is a VEGFR inhibitor that potently suppresses human tumor angiogenesis. SKLB610 inhibited angiogenesis-related tyrosine kinase VEGFR2, fibroblast growth...

CAS 212142-18-2 Vatalanib succinate

Vatalanib succinate
(CAS: 212142-18-2)

Vatalanib succinate is a potent and orally bioactive VEGFR inhibitor (IC50 =37 and 77 nM for VEGFR-2 and -1, respectively) exhibiting potential antineoplastic a...

Chemical Structure

CAS 656247-17-5 Nintedanib

Quick Inquiry

Verification code

Featured Items